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INTRODUCTION
Schizophrenia is a severe mental disorder and considered a pu ­
blic health issue. The cost of schizophrenia includes lost income, 
public aid, and drug and psychosocial treatments(1). Despite all the 
treatments currently available, patients with schizophrenia still suffer 
from a combination of symptoms, such as delusions, hallucinations, 
and social withdrawal(1,2).
Among many hypotheses for schizophrenia’s etiology, the neu­
rodevelopmental model is one of the most important(3). The visual 
pathway may be a good marker for central nervous system develop­
ment. The recent advances in understanding the neural networks 
involved in visual perception allow a better comprehension of the pa­
thophysiology of neurodevelopmental and psychiatric disorders(4,5).
Schizophrenia patients’ exhibit deficits in several neurophysiolo­
gic measures of information processing that have been proposed as 
candidate endophenotypes(6). A number of studies that provide evi­
dence to support the hypothesis that the deficit in the magnocellular 
pathway is a trait of vulnerability to schizophrenia(7,8).
Deficits in visual performance of patients with schizophrenia 
have been described for many years, but this may be due to several 
factors, from peripheral sensory abnormalities (slow neuronal trans­
mission) to losses in higher cortical functioning(6,9­11). Furthermore, fai­
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ABSTRACT
Background: Visual processing deficits have been reported for patients with schi ­
zophrenia. Previous studies demonstrated differences in early­stage processing of 
schizophrenics, although the nature, extent, and localization of the disturbance 
are unknown. The magnocellular and parvocellular visual pathways are associa­
ted with transient and sustained channels, but their respective contributions to 
schizophrenia­related visual deficits remains controversial.
Purpose: The aim of this study was to evaluate magnocellular dysfunction in 
schi zophrenia using frequency doubling technology. 
Methods: Thirty­one patients with schizophrenia and 34 healthy volunteers were 
examined. Frequency doubling technology testing was performed in one session, 
consisting of a 15­minute screening strategy followed by the C­20 program for 
frequency doubling technology. 
Results: Schizophrenic patients showed lower global mean sensitivity (30,97 ± 
2,25 dB) compared with controls (32,17 ± 3,08 dB), p<0.009. Although there was no 
difference in the delta sensitivity of hemispheres, there was a difference in sensitivity 
analysis of the fibers crossing the optic chiasm, with lower mean sensitivity in the 
patient group (28,80 dB) versus controls (30,66 dB). The difference was higher in 
fibers that do not cross the optic chiasm, with lower mean sensitivity in patients 
(27,61 dB) versus controls (30,26 dB), p<0.005. 
Conclusions: Our results suggest that there are differences between global sen ­
sitivity and fiber sensitivity measured by frequency doubling technology. The 
different sensitivity of fibers that do not cross the optic chiasm is consistent with 
most current etiological hypotheses for schizophrenia. The decreased sensitivity 
responses in the optic radiations may significantly contribute to research assessing 
early­stage visual processing deficits for patients with schizophrenia. 
Keywords: Schizophrenia; Visual perception; Visual pathways; Basal nucleus of 
Meynert
RESUMO
Histórico: Déficits de processamento visual foram relatados em pacientes com 
esquizofrenia. Estudos anteriores demonstraram diferenças no estágio inicial de pro-
cessamento de esquizofrênicos, embora a natureza, extensão e localização do distúrbio 
são desconhecidas. As vias magnocelulares e parvocelular visuais são associados com 
canais transitórios e sustentado, mas suas respectivas contribuições para a esquizofrenia 
relacionados com déficits visuais permanece controverso.
Objetivo: Avaliar a disfunção magnocelular na esquizofrenia usando a tecnologia 
de frequência dupla. 
Métodos: Trinta e um pacientes com esquizofrenia e 34 voluntários saudáveis  foram 
examinados. Tecnologia de frequência dupla foi realizada em uma sessão, consistin-
do de uma estratégia de rastreio de 15 minutos, seguido do programa de C-20 para 
tecnologia de frequência dupla. 
Resultados: Os pacientes esquizofrênicos apresentaram sensibilidade média inferior 
global (30,97 ± 2,25 dB), em comparação com os controles (32,17 ± 3,08 dB), p<0,009. 
Embora não tenha ocorrido diferença na sensibilidade do delta de hemisférios, houve 
uma diferença na análise de sensibilidade das fibras que atravessam a quiasma, com 
menor sensibilidade média no grupo de pacientes (28,80 dB) versus controlos (30,66 
dB). A diferença foi maior em fibras que não cruzam o quiasma óptico, com menor 
sensibilidade média em pacientes (27,61 dB) versus controles (30,26 dB), p<0,005. 
Conclusões: Nossos resultados sugerem que há diferenças entre a sensibilidade global 
e sensibilidade da fibra medida pela tecnologia de frequência dupla. A sensibilidade 
diferente de fibras que não cruzam o quiasma óptico é compatível com a maioria 
das atuais hipóteses etiológicas para a esquizofrenia. As respostas diminuição da 
sensibilidade nas radiações ópticas podem contribuir significativamente para pes-
quisar a avaliação em estágio inicial déficits de processamento visual em pacientes 
com esquizofrenia.
Descritores: Esquizofrenia; Percepção visual; Vias visuais; Núcleo basal de Meynert
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lures in this system cause a lack of information to the visual cortex, and 
these result in clinical symptoms for patients(12). The most frequent 
clinical symptoms include selective attention in sustained attention 
and disturbance of short­term visual memory(13­15). 
The subcortical projections of the retina to the cerebral cortex are 
formed mainly by two pathways (magnocellular and parvocellular) 
related to subdivisions of the lateral geniculate body with the same 
name. These pathways are of great importance because they contain 
approximately 90% of axons leaving the retina and maintain their 
anatomical segregation of projections through the lateral geniculate 
body in the V1 layer 4C of the striate cortex(14). 
Psychophysical studies of specific visual functions have been 
used to measure visual performance and understand retinal ganglion 
cell functioning. Some studies suggested that the visual deficit is in 
the magnocellular pathway, or the transient channels. Other studies 
claim that the visual deficit is in the parvocellular pathway or the 
sustained channels, or the interaction of the abnormal magnocellular 
and parvocellular channels(16­18). Although many studies have establi­
shed that there are differences in early visual processing in schizo­
phrenia patients, the nature, extent, and location of this abnormality 
remain uncertain(19,20). 
The magnocellular pathway is formed by large neurons that 
pro ject the visual stimuli to the dorsal visual stream, and is primarily 
involved with the motion and location of the stimulus (the “where” 
system)(20). The parvocellular pathway is composed of smaller neu­
rons, with slower neuronal driving, which project to the ventral visual 
stream and is primarily responsible for recognition of the object (the 
“what” system). Despite the preference of the dorsal and ventral mag­
nocellular and parvocellular neurons, visual information also crosses 
between hemispheres(20).
The physiological responses of ganglion cells in the magnocel­
lular and parvocellular pathways are similar in some domains and 
completely different in others. The major difference is the response 
to color sensitivity. Parvocellular neurons respond to the stimulus of 
alternation green/red or blue/yellow, and show some response des­
pite the change of color luminescence. In the case of magnocellular 
neurons, there is no response to alternation of colors when the lumi­
nescence is balanced(21).
Another difference in physiological responses between parvo­
cellular and magnocellular neurons is present in contrast sensitivity. 
The response to contrast sensitivity is much greater in magnocellular 
cells, which respond to stimuli with contrast less than 2%, while the 
parvocellular cells rarely respond to a contrast less than 10%(20,21).In 
other dimensions of visual stimuli, including spatial response, tem­
poral, and luminescence contrast, neurons via the parvocellular and 
magnocellular pathways have different responses; however, there is 
overlap in the rates of sensitivity(20).
The aim of this study was to evaluate the initial visual processing 
(perception of the stimulus by ganglion cells) using frequency dou­
bling technology (FDT) in patients with schizophrenia compared 
with healthy controls, and evaluate the relationship between the 
deficit in visual processing with socio­demographic factors and cli­
nical factors associated with chronicity, such as negative symptoms, 
duration of the disease, and antipsychotic drug use.
METHODS
ParticiPants
We recruited patients with diagnoses of schizophrenia from the 
Schizophrenia Program at the Federal University of São Paulo. The 
control group was recruited from the hospital staff community and 
students at the same university. The participation of individuals in the 
study was voluntary and all signed the Term of Free and Informed 
Consent, previously approved by the Ethics Committee of the Federal 
University of São Paulo.
Inclusion criteria for patients included: 1) fulfill the diagnosis of 
schi zophrenia made through the application of the Structured Cli­
nical Interview for DSM-IV (SCID) by a trained psychiatrist; 2) good 
vision (visual acuity greater 20/60) tested by Snellen chart; 3) intrao­
cular pressure lower than 20 mmHg measured by Perkins tonometry; 
and 4) normal biomicroscopic examination and normal optic nerve 
(excavation/disc equal to or less than 0.6 SD) assessed by a ophthal­
mologist(22).
The exclusion criteria for patients included: 1) presence of a his ­
tory of abuse on alcohol or drugs; 2) presence of any neurological 
disease that could affect performance on the test; and 3) diseases 
aff ecting the visual field.
The inclusion criteria for controls: 1) mental status assessment by 
Self­Report Questionnaire (SRQ­20) with cut­off less than or equal to 
7 positive answers; and 2) the same ophthalmologic inclusion criteria 
applied for the schizophrenic patients. A family history of glaucoma 
was allowed(23).
The exclusion criteria for controls: 1) presence of psychiatric illness; 
2) substance abuse; 3) diseases affecting the visual field; and 4) presen­
ce of a systemic disease that can potentially affect the visual system.
Psychiatric assessment
The presence of positive and negative symptoms was assessed 
by the Positive and Negative Syndromes Scale (PANSS)(24). Schizoph­
renic patients were classified into negative, positive, or mixed accor­
ding to the parameters of Andreasen and Olsen(24).
Patients were evaluated and classified according to antipsychotic 
medication in use. The type of antipsychotics included first and se­
cond generation antipsychotics or a combination of both. The dose 
of chlorpromazine equivalents for each antipsychotic used at the 
time of examinations was calculated.
Control participants were evaluated with the SRQ­20 and were 
excluded from the study if their scores were higher than 7.
OPhthalmOlOgic evaluatiOn
Participants were submitted to an ophthalmological examina­
tion, which included: measurement of visual acuity, refraction, slit­lamp 
biomicroscopy of the anterior chamber, measurement of intraocular 
pressure, and fundus examination. 
Patients and volunteers were tested: light stimuli were presented 
and participants responded according to their ability to detect the 
stimuli. Participants first received the necessary instructions for per­
forming the examination. Next, participants began a 15­minute stra­
tegy of screening, where participants learned to recognize the stimuli 
and adapt to the test. The stimuli were presented on the computer 
screen and the participants were required to press a button when 
they saw the gray square. Testing was conducted in a darkened room.
FDT measures the contrast needed for detection of the stimulus. 
Each grating target is a square extending approximately 10º in diame­
ter. Targets are presented in one of 18 areas located 20° radius of the 
visual field temporally and 30º nasally(25). FDT was performed with the 
C­20 program, which is the proper evaluation of the magnocellular 
cells, using a sinusoidal pattern of light stimuli and temporal fre­
quency of 50 Hz(25,26). FDT was measured with the frequency doubling 
visual field instrument (Carl Zeiss Meditec, Dublin, CA).
statistical analysis
The analyses of FDT global retinal sensitivity were performed 
com paring the mean­deviation (MD) of patients versus controls using 
unpaired t test. The right hemisphere analysis included the mean 
sensitivity of the right nasal and left temporal hemifields. The left 
hemisphere analysis included the mean sensitivity of the right tem­
poral and left nasal hemifields. We also performed a retinal sensitivity 
analysis between the fibers crossing the optic chiasm and those that 
do not cross.
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Statistical analyses were performed using the SPSS statistical pa­
ckage, version 17.0, (SPSS Inc., Chicago, USA). Generalized estimated 
equation (GEE) was performed to evaluate differences among the 
groups and to correct the dependency between the eyes, accor­
ding to hemispheres, and fibers that cross or do not cross the optic 
chiasm(27).
As a secondary analysis, MD values were used as the dependent 
variable in the logistic regression model with the following indepen­
dent variables: age, gender, disease duration, antipsychotic treat­
ment, positive and negative symptoms, and education level. 
RESULTS
We evaluated 31 outpatients (24 male/7 female) diagnosed with 
schizophrenia using the SCID criteria of the DSM­IVR, and 34 health 
controls (8 male/26 female). The participants’ socio­demographic 
characteristics are described in table 1. The ophthalmologic evalua­
tion revealed that both groups had visual acuity, as tested by Snellen 
chart, that was higher than 20/60 (Table1). Intraocular pressure was 
normal (less than 20 mmHg) for both groups, although there was 
a significant difference between groups of less than 2 mmHg. This 
difference is not clinically relevant and cannot affect the FDT results. 
In the sample studied, only two patients were employed at the 
time of evaluation; the remaining 32 (94%) were retired or receiving 
sickness benefit.
All patients were using antipsychotic drugs or other psychotropic 
agents for at least 6 months. The patients were also assessed by the 
PANSS scale and classified according to symptomatic group: ten were 
classified as negative type, ten were positive type, 11 were any kind, 
and three were mixed type. The participants’ clinical characteristics 
are described in table 2.
Table 3 shows the global MD FDT test in control and schizophrenia 
groups. Three patients were excluded from the FDT analysis due to 
poor performance on the test.
The patients with schizophrenia showed lower global mean 
sensitivity values (30.97 dB ± 2.25) in comparison with the control 
group mean (32.17 dB ± 3.08), p<0.009. There was no difference in 
the delta sensitivity of hemispheres between patients and controls 
(p<0.88) (Figure1). 
There was a difference in sensitivity analysis of the fibers crossing 
the optic chiasm between patients and controls, with lower mean 
sensitivity in the schizophrenia group (28.80 dB) than in the control 
group (30.66 dB), p=0.005 (Figure 2). 
The difference in sensitivity analysis of the fibers that did not cross 
the optic chiasm between patients and controls was higher, with 
lower mean sensitivity (27.61 dB) in the patient group versus (3026 dB) 
the control group (p=0.02).
There was no significant correlation between the global mean 
sensitivity values and the following independent variables: age, gen­
der, length of time with diagnoses, antipsychotics used, presence or 
absence of positive and negative symptoms, and education level. 
DISCUSSION
This study evaluated the visual processing deficits in schizo­
phrenia by use of FDT. The advantages of FDT for early detection of 
magnocellular dysfunction are well documented. FDT shows good 
specificity (86­100%) at high sensitivity (93%), and has global indices 
that correlate highly with those of standard perimetry(26). The finding 
in this study of a deficit in the magnocellular pathway in schizophre­
nia is consistent with results from some previous psychophysical 
studies, although they have also produced conflicting results(28).
A number of psychophysical tests have been used to measure 
visual performance and to understand retinal ganglion cell deficits 
in schizophrenia(8,28). Some studies using a visual backward masking 
paradigm, during which participants are asked to detect a stimulus 
Table 1. Socio-demographic characteristics of patients with schizo-
phrenia and healthy control participants
Control 
(n=34)
Schizophrenic
(n=31) p-value
Gender (M/F) (8/26) (24/7) 0.005
VA (logMAR) ­ Mean (SD) 00.01 (0.04) 00.04 (00.06) 0.100
Age (years) ­ Mean (SD) 32.10 (13.7) 37.80 (12.30) 0.081
IOP (mmHg) ­ Mean (SD) 12.16 (2.44) 14.13 (02.99) 0.005
Refraction ­ Mean (SD) ­0.33 (1.41) ­0.21 (02.81) 0.835
M= male; F= female; SD= standard deviation; IOP= intraocular pressure; VA= visual acuity; 
Refraction= espheric equivalent.
Table 2. Clinical characteristics of the schizophrenic patients
Patients (n = 34) Mean SD Range
Disease duration (years) 014.32 010.71 1 ­ 53
Age of onset (years) 022.76 008.79 12 ­ 40
PANSS­N 019.76 005.85 7 ­ 34
PANSS­P 018.38 007.25 9 ­ 34
GAF 043.94 011.05 20 ­ 65
CPZ (mg/d) 367.50 242.56 50 ­ 1175
SD= standard deviation; PANSS­N= negative PANSS score; PANSS­P= positive PANSS score; 
GAF= Global Assessment of Functioning scale score; CPZ= chlorpromazine equivalent 
(mg/day).
Table 3. FDT results of global mean retinal sensitivity (FDT-MD) of 
schizophrenic patients and healthy control
Schizophrenic
n=31
Control
n=34 p-value
FDT­MD (dB)
Mean (SD)
30.97 (2.25) 32.17 (3.08) p<0.009
FDT­MD (dB)
Crossing fibers
28.80 (5.02) 30.66 (2.48) P=0.005
FDT­MD (dB)
N­crossing fibers
27.61 (5.49) 30.26 (2.83) P=0.002
Delta MD 28.58 (6.38) 30.43 (2.66) P<0.88
FDT­MD = global mean sensitivity values; crossing fibers= fibers that cross the optic chiasm; 
n­crossing fibers= fibers that do not cross the optic chiasm; Delta MD= delta sensitivity of 
hemispheres.
immediately followed by a mask, increased the possibility that the 
mask, which is processed by an overactive magnocellular pathway, 
may influence the lower performances on target detections(18,29).
Studies using luminance contrast sensitivity measurements sho­
wed more pronounced differences. Schwartz et al.(15) found selective 
contrast sensitivity impairments for temporally modulated low fre­
quency gratings, which stimulate magnocellular neurons. Kéri et al.(30) 
observed intact contrast sensitivity for magnocellular pathway stimuli.
A limitation of this study is that there has not been extensive 
tes ting of its psychophysical properties. Furthermore, the impact of 
training requires better investigation and test­retest reliability should 
be measured, especially in patients with cognitive impairments(31).
New evidence from functional magnetic resonance imaging sup­
ports the hypothesis that schizophrenia is associated with impaired 
functioning of the magnocellular pathway and that these deficits 
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may contribute to high­order cognitive deficits(32). Based on previous 
available data, it was hypothesized that a negative correlation would 
be found such that patients with the highest level of negative 
symptoms would show the greatest deficit in the magnocellular pa­
thway(33). In general, the results of the contrast sensitivity and masking 
studies suggest that visual processing is more intact in groups with 
predominantly positive symptoms and good premorbid history. In 
our sample, there was no correlation between length of time with 
the disease and age of onset.
In this study all patients were using antipsychotic drugs or other 
psychotropic agents for at least 6 months, and the medication effect 
cannot be excluded. Dopamine is present in the retina and there 
is evidence that a hypo­dopaminergic state could affect contrast 
sensitivity and color perception(34). However, previous studies have 
shown no significant correlations between the antipsychotic dose 
and deficits in the magnocellular pathway(32,33). In contrast, Braff and 
Saccuzzo(35) found that medications reduced the backward masking 
deficit. In our sample, there was no correlation between FDT response 
and chlorpromazine­equivalent doses.
There is some evidence in literature that supports a right hemis­
phere advantage for processing global information, and left hemis­
phere preference for local information(36). In our study, there was no 
difference in the delta sensitivity of hemispheres between patients 
and controls. However, Braus et al.(37) used functional magnetic re­
sonance imaging and found a hypoactivation in the magnocellular 
pathway, particularly in the right hemisphere of schizophrenic pa­
tients, but found no evidence of abnormal functioning in the area of 
the parvocellular pathway. 
It was possible to verify the difference in sensitivity analysis of 
the fibers that do not cross the optic chiasm between patients and 
controls because of the particularities of ganglion cell anatomy(38). 
The ganglion cells of the right and left eye visual receptive fields re­
flect half of the visual field in the opposite hemisphere. The crossing 
of fibers occurs in the retinal optic chiasm, where medial fibers cross 
the chiasm to join sides with the temporal fibers. In other words, the 
temporal retina ipsilateral hemispheric projection displays in the 
same side, while the nasal retina contralateral hemispheric projection 
displays in the opposite side. Because of this distribution of fibers, 
each outer half of the visual field is represented in the opposite ce­
rebral hemisphere(38).
To the best of our knowledge, this is the first time in the literature 
that analyses of sensitivity between fibers that cross and do not cross 
the chiasm have been performed. The evidence presented here, for 
a lower sensitivity in fibers that do not cross the optic chiasm, is con­
sistent with most current etiological hypotheses for schizophrenia 
involving genetic factors and anatomical processes (e.g., dysmyeli­
nation)(3,39).
Our study showed significant decreased sensitivity responses 
in the optic radiations, which was consistent with the results from 
Butler et al. using diffusion tensor imaging to examine white mat­
ter integrity in schizophrenia(40). The present findings suggest that 
there are differences between global sensitivity and fiber sensitivity 
measured by FDT, and may contribute to a significant body of re­
search to assess early­stage visual processing deficits for patients 
with schizophrenia. 
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